A highly potent human antibody neutralizing all serotypes of BK polyomavirus.

BK polyomavirus infection poses a significant risk to kidney transplant recipients. Reactivation of dormant virus in the transplanted kidney, triggered by immunosuppression, can lead to BK polyomavirus-associated nephropathy in up to 10% of transplants, often resulting in loss of graft function or e...

Full description

Saved in:
Bibliographic Details
Main Authors: Marcel Weber, Simone Schmitt, Barbara Eicher, Jemima Seidenberg, Justina Rutkauskaite, Benedikt Stöckli, Catherine Townsend, Uyen Huynh-Do, Thomas Schachtner, Serena Delbue, Armin Mäder, Christoph Esslinger, Matthias Hillenbrand
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-07-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1013122
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849245716789067776
author Marcel Weber
Simone Schmitt
Barbara Eicher
Jemima Seidenberg
Justina Rutkauskaite
Benedikt Stöckli
Catherine Townsend
Uyen Huynh-Do
Thomas Schachtner
Serena Delbue
Armin Mäder
Christoph Esslinger
Matthias Hillenbrand
author_facet Marcel Weber
Simone Schmitt
Barbara Eicher
Jemima Seidenberg
Justina Rutkauskaite
Benedikt Stöckli
Catherine Townsend
Uyen Huynh-Do
Thomas Schachtner
Serena Delbue
Armin Mäder
Christoph Esslinger
Matthias Hillenbrand
author_sort Marcel Weber
collection DOAJ
description BK polyomavirus infection poses a significant risk to kidney transplant recipients. Reactivation of dormant virus in the transplanted kidney, triggered by immunosuppression, can lead to BK polyomavirus-associated nephropathy in up to 10% of transplants, often resulting in loss of graft function or even graft loss. Currently, there is no specific treatment that reliably prevents BK polyomavirus-associated nephropathy or halts its progression. Standard of care relies on reducing immunosuppression, allowing the immune system to gradually control the infection but at the risk of provoking rejection episodes and compromising kidney function. This study describes the discovery and characterization of a highly-potent BK polyomavirus-neutralizing antibody, identified from a kidney transplant recipient who displayed rapid clearance of high-level BKPyV-DNAemia. Antibody mAb 319C07 (USAN potravitug) neutralizes all four BK polyomavirus serotypes and recognizes an epitope critical for viral cell attachment. mAb 319C07 is in clinical development for the treatment of BKPyV infection in renal transplant patients (NCT05769582).
format Article
id doaj-art-0b138efe67fc43c19fcea2a0cc7e225b
institution Kabale University
issn 1553-7366
1553-7374
language English
publishDate 2025-07-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Pathogens
spelling doaj-art-0b138efe67fc43c19fcea2a0cc7e225b2025-08-20T03:58:44ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742025-07-01217e101312210.1371/journal.ppat.1013122A highly potent human antibody neutralizing all serotypes of BK polyomavirus.Marcel WeberSimone SchmittBarbara EicherJemima SeidenbergJustina RutkauskaiteBenedikt StöckliCatherine TownsendUyen Huynh-DoThomas SchachtnerSerena DelbueArmin MäderChristoph EsslingerMatthias HillenbrandBK polyomavirus infection poses a significant risk to kidney transplant recipients. Reactivation of dormant virus in the transplanted kidney, triggered by immunosuppression, can lead to BK polyomavirus-associated nephropathy in up to 10% of transplants, often resulting in loss of graft function or even graft loss. Currently, there is no specific treatment that reliably prevents BK polyomavirus-associated nephropathy or halts its progression. Standard of care relies on reducing immunosuppression, allowing the immune system to gradually control the infection but at the risk of provoking rejection episodes and compromising kidney function. This study describes the discovery and characterization of a highly-potent BK polyomavirus-neutralizing antibody, identified from a kidney transplant recipient who displayed rapid clearance of high-level BKPyV-DNAemia. Antibody mAb 319C07 (USAN potravitug) neutralizes all four BK polyomavirus serotypes and recognizes an epitope critical for viral cell attachment. mAb 319C07 is in clinical development for the treatment of BKPyV infection in renal transplant patients (NCT05769582).https://doi.org/10.1371/journal.ppat.1013122
spellingShingle Marcel Weber
Simone Schmitt
Barbara Eicher
Jemima Seidenberg
Justina Rutkauskaite
Benedikt Stöckli
Catherine Townsend
Uyen Huynh-Do
Thomas Schachtner
Serena Delbue
Armin Mäder
Christoph Esslinger
Matthias Hillenbrand
A highly potent human antibody neutralizing all serotypes of BK polyomavirus.
PLoS Pathogens
title A highly potent human antibody neutralizing all serotypes of BK polyomavirus.
title_full A highly potent human antibody neutralizing all serotypes of BK polyomavirus.
title_fullStr A highly potent human antibody neutralizing all serotypes of BK polyomavirus.
title_full_unstemmed A highly potent human antibody neutralizing all serotypes of BK polyomavirus.
title_short A highly potent human antibody neutralizing all serotypes of BK polyomavirus.
title_sort highly potent human antibody neutralizing all serotypes of bk polyomavirus
url https://doi.org/10.1371/journal.ppat.1013122
work_keys_str_mv AT marcelweber ahighlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT simoneschmitt ahighlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT barbaraeicher ahighlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT jemimaseidenberg ahighlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT justinarutkauskaite ahighlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT benediktstockli ahighlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT catherinetownsend ahighlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT uyenhuynhdo ahighlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT thomasschachtner ahighlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT serenadelbue ahighlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT arminmader ahighlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT christophesslinger ahighlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT matthiashillenbrand ahighlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT marcelweber highlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT simoneschmitt highlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT barbaraeicher highlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT jemimaseidenberg highlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT justinarutkauskaite highlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT benediktstockli highlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT catherinetownsend highlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT uyenhuynhdo highlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT thomasschachtner highlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT serenadelbue highlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT arminmader highlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT christophesslinger highlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus
AT matthiashillenbrand highlypotenthumanantibodyneutralizingallserotypesofbkpolyomavirus